Latest metastatic melanoma Stories

Combining CT imaging findings with baseline serum lactate dehydrogenase levels is showing promise as a way to predict survival in patients with metastatic melanoma being treated with anti-angiogenic therapy. With the hope of predicting patient survival, researchers at the University of Mississippi Medical Center in Jackson and at the Ohio State University Comprehensive Cancer Center in Columbus analyzed CT images and clinical data from 46 patients with metastatic melanoma that were treated...

SAN DIEGO, Nov. 15, 2012 /PRNewswire/ -- OncoSec Medical Inc. (OTCBB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumors, announces positive preliminary results from a Phase II trial investigating the use of ImmunoPulse in metastatic melanoma patients at the 6th World Meeting of Interdisciplinary Melanoma Skin Cancer Centres & 8th EADO Congress. This preliminary interim analysis of 13 out of 25 patients...

MELBOURNE, Australia, Oct. 25, 2012 /PRNewswire/ -- Specialised Therapeutics Australia Pty Ltd today announced that abstracts for the upcoming Society for Melanoma Research meeting have been published online in the organization's official journal at http://onlinelibrary.wiley.com/doi/10.1111/pcmr.12023/abstract. The publication includes an abstract reviewing results from a phase III metastatic melanoma study with ABRAXANE(®) (nanoparticle albumin-bound paclitaxel). In the...

Oral BRAF inhibitor can extend survival to 16 months for some patients An international team of researchers from the United States and Australia, including researchers at Moffitt Cancer Center in Tampa, Fla., have found that the oral BRAF inhibitor vemurafenib (PLX4032) when tested in a phase II clinical trial offered a high rate of response in patients with previously treated metastatic melanoma and who had the BRAF mutation. More than 50 percent of the patients in the trial had positive,...

A report published this week in the New England Journal of Medicine shows that the 50 percent of metastatic melanoma patients with a specific genetic mutation benefit from the drug Vemurafenib – increasing median survival from about 6 months to 15.9 months. In patients who responded, the drug stopped cancer progression for a median 6.7 months. “For melanoma patients with a BRAF V600 mutation, this drug is a breakthrough. Not a cure, but a major breakthrough,” says Karl Lewis, MD,...

(Ivanhoe Newswire) – About 70,000 people are diagnosed with melanoma every year in the United States. Of those, nearly 8,000 people will die of the disease. However there is good news. For the first time, researchers are able to report that a newly approved drug for patients with metastatic melanoma nearly doubles median survival times, a finding that will change the way this deadly form of skin cancer is treated. "About 50 percent of patients with metastatic melanoma, or 4,000 people a...

Vanderbilt-Ingram Cancer Center researchers helped lead trial Investigators from Vanderbilt-Ingram Cancer Center (VICC) and 12 other centers in the United States and Australia have found that a new drug for patients with metastatic melanoma nearly doubled median overall survival. More than half of patients who were treated with the novel drug vemurafenib, known commercially as Zelboraf, responded to treatment and experienced an impressive median overall survival of nearly 16 months –...

Researchers from UCLA's Jonsson Comprehensive Cancer Center, together with scientists from 12 other sites in the United States and Australia, report for the first time that a newly approved drug for patients with metastatic melanoma nearly doubles median survival times, a finding that will change the way this deadly form of skin cancer is treated. The data comes from an international Phase II study of Zelboraf that included 132 patients followed for at least one year. Patients with this...

Drug used to treat melanoma with 1 mutation sets off a cascade that results in a different type of skin cancer in cells with another mutation Patients with metastatic melanoma taking the recently approved drug vemurafenib (Zelboraf®) responded well to the twice daily pill, but some of them developed a different, secondary skin cancer. Now, researchers at UCLA's Jonsson Comprehensive Cancer Center, working with investigators from the Institute of Cancer Research in London, Roche and...

SAN DIEGO, Jan. 18, 2012 /PRNewswire/ -- OncoSec Medical Incorporated (OTCBB:ONCS), which is developing its advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumor cancers, presented its corporate strategy for 2012 and reported on progress since launch of the company last year at the Biotech Showcase and OneMedForum conferences held January 9-13 in San Francisco, CA. (Logo: http://photos.prnewswire.com/prnh/20110314/MM64943LOGO) "Despite a...